Overview
The Department of Health has been notified of a critical shortage of rifampicin 300mg capsules. While an alternative S19a product has now been approved for use by the Therapeutic Goods Administration (TGA), there remain concerns that supplies will be insufficient to meet the current demand in Victoria. As such, there is a need to consider implementing measures to conserve rifampicin 300mg capsules where possible.
A Clinical Advisory Group including representative from HealthShare Victoria, Safer Care Victoria, and the Department of Health, is coordinating the response to ensure safety and continuity of clinical care, including best practice in antimicrobial stewardship. This group is currently assessing the supply of rifampicin and reviewing clinical indications of rifampicin with a view to provide guidance on conservation.
This is an evolving situation and Safer Care Victoria alongside the Department of Health will continue to monitor and provide critical updates as they are available.
Situation
The TGA has advised of a shortage of rifampicin 300mg due to global manufacturing issues and that this shortage will likely continue until 30 January 2026. While the TGA has approved an S19A alternative product from Sanofi, there remain concerns that this supply will not be able to meet current stock requirements in Victoria.
Actions
Health services are required to take the following initial actions. This is a rapidly evolving situation, and further advice will be provided once available.
Stock allocation and reporting
- HealthShare Victoria will allocate S19A stock to health services. Orders should not be placed by health services.
- Patients receiving treatment for tuberculosis will be prioritised and health services should continue to place orders for this through the Royal Melbourne Hospital’s Victorian Tuberculosis Program.
- Health services will be requested to report stock on hand to HealthShare Victoria.
Conservation
Conserve rifampicin use where possible, prioritising indications where no suitable alternatives exist (e.g. active tuberculosis).
- Clinicians should review all patients currently prescribed rifampicin and carefully assess whether ongoing treatment is essential. Before continuing rifampicin, consider whether therapy can be safely ceased, an alternative agent used, or if continued use is critical for the patient’s care.
- Further advice on conservation strategies will be released over the coming weeks.
Alternative products
Where rifampicin is required:
- Prioritise use of S19A approved alternatives, where available.
- Consider internationally registered alternatives via the TGA Special Access Scheme (SAS) if S19A supplies are insufficient:
- From the USA (Pro Pharmaceuticals Group, Medsurge) – bottle of 30 or 60 capsules.
- From Belgium (Medsurge) – bottles of 50 capsules (not labelled in English, but active ingredient and strength are clearly distinguishable).
This is an evolving situation and Safer Care Victoria alongside the Department of Health will continue to monitor and provide critical updates as they are available.
Reviewed 27 June 2025